New drug trial aims to slow vision loss in rare genetic eye disease
Disease control
Recruiting now
This clinical trial is testing whether a medication called tinlarebant can slow the progression of Stargardt disease, a genetic condition that causes vision loss. The study involves 60 participants who will take either the drug or a placebo daily for two years while researchers m…
Phase: PHASE2, PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Feb 23, 2026 14:53 UTC